WO2023232003A1 - Anticorps anti-hbsag et son utilisation - Google Patents

Anticorps anti-hbsag et son utilisation Download PDF

Info

Publication number
WO2023232003A1
WO2023232003A1 PCT/CN2023/096996 CN2023096996W WO2023232003A1 WO 2023232003 A1 WO2023232003 A1 WO 2023232003A1 CN 2023096996 W CN2023096996 W CN 2023096996W WO 2023232003 A1 WO2023232003 A1 WO 2023232003A1
Authority
WO
WIPO (PCT)
Prior art keywords
seq
sequence shown
antibody
antibodies
hbsag
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
PCT/CN2023/096996
Other languages
English (en)
Chinese (zh)
Inventor
王铁军
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Anhui Ronghang Biotech Development Co Ltd
Original Assignee
Anhui Ronghang Biotech Development Co Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Anhui Ronghang Biotech Development Co Ltd filed Critical Anhui Ronghang Biotech Development Co Ltd
Publication of WO2023232003A1 publication Critical patent/WO2023232003A1/fr
Anticipated expiration legal-status Critical
Ceased legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/42—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum viral
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/20—Antivirals for DNA viruses
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/08—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from viruses
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
    • C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
    • C12N5/10—Cells modified by introduction of foreign genetic material

Definitions

  • the present invention relates to anti-HBsAg antibodies. More specifically, the present invention relates to tetravalent antibodies that bind to HBsAg and corresponding heavy chain antibodies. The invention also relates to pharmaceutical compositions comprising these antibodies and their medicinal uses.
  • Hepatitis B is a disease caused by Hepatitis B Virus (HBV) infecting the body.
  • HBV Hepatitis B Virus
  • Hepatitis B virus is a hepatotropic virus that mainly exists in liver cells and damages liver cells, causing liver cell inflammation, necrosis, and fibrosis.
  • Hepatitis B virus is divided into two types: acute and chronic. Acute hepatitis B in adults can mostly resolve spontaneously through their own immune mechanisms.
  • chronic hepatitis B (CHB) has become a great challenge to global health care and is also the main cause of chronic liver disease, cirrhosis and hepatocellular carcinoma. WHO estimates that in 2019, 296 million people were living with chronic hepatitis B infection (defined as hepatitis B surface antigen positivity). Approximately one-third of patients with chronic hepatitis B develop cirrhosis, liver failure, and hepatocellular carcinoma, resulting in 600,000 deaths annually.
  • HBV consists of (i) an envelope containing three related surface proteins (collectively known as hepatitis B surface antigen, HBsAg) and lipids and (ii) an icosahedral nucleocapsid that surrounds the viral DNA genome and DNA polymerase.
  • a short linear domain in the cytoplasmic pre-S region interacts with binding sites on the capsid surface. Viral particles are then secreted into the blood.
  • SVP subviral particles
  • SVP is non-infectious due to the lack of nucleocapsids.
  • SVP is greatly involved in disease progression, especially the immune response to hepatitis B virus.
  • the amount of SVP is at least 10,000 times the amount of virus, trapping the immune system and weakening the body's immune response to hepatitis B virus.
  • High levels of HBsAg can deplete HBsAg-specific T cell responses and are thought to be an important factor in viral immune tolerance in patients with chronic hepatitis B.
  • anti-HBV drugs currently approved for marketing are mainly immunomodulators (interferon- ⁇ and peginterferon- ⁇ -2 ⁇ ) and antiviral therapeutic drugs (lamivudine, adefovir dipivoxil, entecavir, tecavir, etc.). Bivudine, tenofovir, clavudine, etc.).
  • antiviral therapeutic drugs are nucleoside drugs. Their mechanism of action is to inhibit the synthesis of HBV DNA and cannot directly reduce HBsAg levels. As with extended therapy, nucleoside agents showed HBsAg clearance rates similar to those observed in nature.
  • Current clinical first-line drugs, including nucleoside and interferon drugs do not have the effect of reducing the level of the antigen HBsAg, let alone clearing HBsAg.
  • the invention provides an IgG type tetravalent antibody that binds to hepatitis B surface antigen (HBsAg) or a subviral particle (SVP) containing HBsAg, wherein the tetravalent antibody comprises two heavy chains and two A light chain, each of the heavy chain and the light chain comprising as a variable region a VHH portion comprising CDR1, CDR2, CDR3, wherein:
  • CDR1 includes the sequence shown in SEQ ID NO: 4
  • CDR2 includes the sequence shown in SEQ ID NO: 5
  • CDR3 includes the sequence shown in SEQ ID NO: 6;
  • CDR1 includes the sequence shown in SEQ ID NO: 11
  • CDR2 includes the sequence shown in SEQ ID NO: 12
  • CDR3 includes the sequence shown in SEQ ID NO: 13;
  • CDR1 includes the sequence shown in SEQ ID NO: 18
  • CDR2 includes the sequence shown in SEQ ID NO: 19
  • CDR3 includes the sequence shown in SEQ ID NO: 20;
  • CDR1 contains the sequence shown in SEQ ID NO: 25
  • CDR2 contains the sequence shown in SEQ ID NO: 26
  • CDR3 contains the sequence shown in SEQ ID NO: 27;
  • CDR1 includes the sequence shown in SEQ ID NO: 32
  • CDR2 includes the sequence shown in SEQ ID NO: 33
  • CDR3 includes the sequence shown in SEQ ID NO: 34.
  • the invention provides a heavy chain antibody that binds to hepatitis B surface antigen (HBsAg) or a subviral particle (SVP) comprising HBsAg, wherein the heavy chain antibody comprises a VHH as a heavy chain variable region part, the VHH part includes CDR1, CDR2, CDR3, where:
  • CDR1 includes the sequence shown in SEQ ID NO: 4
  • CDR2 includes the sequence shown in SEQ ID NO: 5
  • CDR3 includes the sequence shown in SEQ ID NO: 6;
  • CDR1 includes the sequence shown in SEQ ID NO: 11
  • CDR2 includes the sequence shown in SEQ ID NO: 12
  • CDR3 includes the sequence shown in SEQ ID NO: 13;
  • CDR1 includes the sequence shown in SEQ ID NO: 18
  • CDR2 includes the sequence shown in SEQ ID NO: 19
  • CDR3 includes the sequence shown in SEQ ID NO: 20;
  • CDR1 contains the sequence shown in SEQ ID NO: 25
  • CDR2 contains the sequence shown in SEQ ID NO: 26
  • CDR3 contains the sequence shown in SEQ ID NO: 27;
  • CDR1 includes the sequence shown in SEQ ID NO: 32
  • CDR2 includes the sequence shown in SEQ ID NO: 33
  • CDR3 includes the sequence shown in SEQ ID NO: 34.
  • the invention provides a nucleotide sequence comprising a polynucleotide encoding any of the above antibodies.
  • the present invention also provides a vector comprising the aforementioned nucleotide sequence.
  • the present invention also provides a host cell comprising the aforementioned vector.
  • the present invention also provides cell lines that produce the antibodies of the present invention, recombinant expression vectors containing the nucleotides of the present invention, and methods for preparing antibodies by culturing antibody-producing cell lines.
  • the present invention provides a pharmaceutical composition
  • a pharmaceutical composition comprising a therapeutically effective amount of any of the above-mentioned antibodies, nucleotide sequences, vectors or host cells, and a pharmaceutically acceptable carrier.
  • the present invention provides the use of any of the above-mentioned antibodies, nucleotide sequences, vectors or host cells in the preparation of medicaments for treating and/or preventing hepatitis B or for preventing diseases caused by hepatitis B.
  • the present invention provides any of the above antibodies, nucleotide sequences, vectors or host cells for treating and/or preventing hepatitis B or for preventing diseases caused by hepatitis B.
  • the present invention provides a method for treating and/or preventing hepatitis B or preventing diseases caused by hepatitis B, which method includes administering an effective amount of any of the above antibodies, nucleotide sequences, and vectors to a subject. or host cells.
  • the hepatitis B is chronic hepatitis B, and the disease caused by hepatitis B is cirrhosis, liver failure or hepatocellular carcinoma caused by hepatitis B.
  • the antibody of the present invention has strong binding force with HBsAg, does not cause the aggregation of HBsAg aggregates, and can effectively reduce HBsAg levels in the body, and can be used to treat and/or prevent hepatitis B-related diseases.
  • Figure 1 Schematic structural comparison of the antibodies constructed in the present invention and control conventional antibodies.
  • Figure 2 Conventional ELISA test to test the binding activity of antibodies to HBsAg.
  • Figure 3 Direct HBsAg ELISA assay tests the effect of antibodies on HBsAg aggregation.
  • Figure 4 Schematic diagram of the experimental process of the HDI-HBV model.
  • “about” means that the value is within an acceptable error range for the specific value as determined by one of ordinary skill in the art, which value depends in part on how it is measured or determined (ie, the limits of the measurement system). For example, “about” in every practice in the art may mean within 1 or more than 1 standard deviation. Alternatively, “about” or “substantially comprising” may mean a range of up to 20%. Furthermore, particularly with respect to biological systems or processes, the term may mean up to an order of magnitude or up to 5 times a value. Unless stated otherwise, when a specific value appears in this application and claims, the meaning of "about” or “substantially comprising” should be assumed to be within an acceptable error range for that specific value.
  • composition or method described herein as “comprising” one or more of the recited elements or steps is open-ended, meaning that the recited element or step is required but may be within the scope of the recited composition or method. Add other components or steps. It will also be understood that any composition or method described as “comprising" one or more of the recited elements or steps also describes a corresponding, more limited composition or method that "consists essentially of” the recited elements or steps, meaning that The composition or method includes such essential elements or steps, and may also include additional elements or steps that do not materially affect the basic and novel characteristics of the composition or method.
  • the term “antibody” refers to any form of antibody that exhibits a desired biological activity, such as inhibiting the binding of a ligand to its receptor or by inhibiting ligand-induced receptor signaling.
  • Antibody fragment and “antigen-binding fragment” refer to antigen-binding fragments of antibodies and antibody analogs, which generally include at least part of the antigen-binding region or variable region (eg, one or more CDRs) of the parent antibody.
  • the antibody is a monoclonal antibody. In other embodiments, the antibody is a polyclonal antibody.
  • the term "monoclonal antibody” as used herein refers to an antibody obtained from a substantially homogeneous population of antibodies, ie, the individual antibodies making up the population are identical except for possible natural mutations that may be present in minor amounts. Monoclonal antibodies are highly specific and target a single antigenic site. Furthermore, in contrast to conventional (polyclonal) antibody preparations, which typically include multiple different antibodies directed against multiple different determinants (epitopes), each monoclonal antibody is directed against only a single determinant on the antigen.
  • the modifier "monoclonal” indicates the character of an antibody obtained from a substantially homogeneous population of antibodies and is not to be understood as requiring that the antibody be prepared by any particular method. For example, monoclonal antibodies for use in the present invention can be prepared by hybridoma or recombinant DNA methods.
  • Monoclonal antibodies may include "chimeric" antibodies, humanized antibodies, or fully human antibodies.
  • the antibody forms part of a larger biomolecule, such as a fusion protein or an antibody drug conjugate.
  • Antibody fragments retain at least some of the binding specificity of the parent antibody. Typically, antibody fragments retain at least 10% of the binding activity of the parent when activity is expressed on a molar basis. Preferably, the antibody fragment retains at least 20%, 50%, 70%, 80%, 90%, 95% or 100% or more of the binding affinity of the parent antibody for the target.
  • multivalent antibody refers to an antibody that contains more than one antigen recognition site (i.e., antigen-binding domain).
  • a "bivalent” antibody has two antigen recognition sites
  • a "tetravalent” antibody has four antigen recognition sites.
  • multivalent antibodies particularly refer to tetravalent antibodies, which are usually engineered to have four antigen-binding sites and are generally not naturally occurring antibodies.
  • a quadrivalent antibody has four binding parts for HBsAg, each of which is capable of binding HBsAg alone.
  • heavy chain antibody refers to an antibody lacking a light chain and consisting only of a heavy chain, which contains two constant regions (CH2 and CH3), a hinge region and a heavy chain variable region (i.e. VHH). Examples include, but are not limited to, native heavy chain antibodies, antibodies naturally lacking light chains, heavy chain antibodies derived from conventional 4-chain antibodies, and engineered antibodies. Heavy chain antibodies may be derived from species of the family Camelidae, such as those produced in camels, llamas, dromedaries, alpacas, and draft horses. Species other than Camelidae may produce heavy chain antibodies that naturally lack light chains; such heavy chain antibodies are within the scope of the invention.
  • single domain antibody refers to a single domain antibody composed only of the heavy chain variable region obtained by cloning the variable region of a heavy chain antibody, also known as VHH (Variable domain of heavy chain of heavy chain antibody) or nanobody (nanobody), is the smallest functional antigen-binding fragment.
  • VHH Very domain of heavy chain of heavy chain antibody
  • nanobody nanobody
  • Single-domain antibodies recognize antigens with high specificity and affinity similar to IgG antibodies, but can better penetrate tumor tissue due to their smaller size ( ⁇ 15 kD).
  • single domain antibodies are resistant to pH extremes, thermal denaturation, proteolysis, solvents, and detergents. They can be expressed and produced in high yields and high solubility.
  • humanized antibody refers to an antibody that contains the CDRs of an antibody derived from a mammal other than human, and the framework regions (FR) and constant regions of a human antibody.
  • chimeric antibody will be considered to refer to any antibody in which the immunoreactive region or site is obtained or derived from a first species and a constant region (which may be complete, partial or in accordance with this openly modified) was obtained from a second species.
  • the target binding region or site will be from a non-human source (eg, mouse or primate) and the constant region is human.
  • an “equivalent” of an antibody or polypeptide refers to an antibody or polypeptide that has a certain degree of homology or sequence identity with the amino acid sequence of the antibody or polypeptide.
  • the sequence identity is at least about 70%, 75%, 80%, 85%, 90%, 95%, 98%, or 99%.
  • equivalents have one, two, three, four or five additions, deletions, substitutions and combinations thereof compared to a reference antibody or polypeptide.
  • equivalents of the antibody or polypeptide retain the activity (eg, epitope binding) or structure (eg, salt bridges) of the reference sequence.
  • a "variant" of a sequence refers to a sequence that differs from the sequence shown at one or more amino acid residues but retains the biological activity of the resulting molecule.
  • Constant substitutions refer to amino acid substitutions known to those skilled in the art, which substitutions are made generally without altering the biological activity of the resulting molecule. In general, it is recognized by those skilled in the art that single amino acid substitutions in non-essential regions of a polypeptide do not substantially change or do not substantially alter the biological activity. "Does not change or does not substantially change” means that one or more aspects have no more than about 20%, about 15%, about 10%, about 9 %, about 8%, about 7%, about 6%, about 5%, about 4%, about 3%, about 2%, or about 1% difference.
  • CDR3 and CDR3 are considered to play a more important role in antigen recognition than other CDRs. Therefore, in the case of substitution, the present invention preferably performs conservative substitutions on CDRs other than CDR3. In some embodiments, CDR3 is not substituted.
  • Preferred amino acid substitutions include, but are not limited to: (1) reducing proteolytic sensitivity, (2) reducing oxidative sensitivity, (3) altering the binding affinity of protein complexes formed, (4) providing or modifying other physical properties of these analogs. Substitution of chemical or functional properties. Analogues may include mutations of various sequences in addition to naturally occurring peptide sequences.
  • single or multiple amino acid substitutions can be made in the naturally occurring sequence, preferably in portions of the polypeptide outside regions where intermolecular contacts are formed.
  • Conservative amino acid substitutions should not substantially alter the structural characteristics of the parent sequence (e.g., amino acid substitutions should not tend to disrupt helices present in the parent sequence, or be characteristic of other secondary structure types that disrupt the parent sequence).
  • the binding domain of the antibody or antigen-binding fragment thereof of the present invention may carry a signal peptide, which is usually located at the N-terminus of the secreted protein and generally consists of 15 to 30 amino acids.
  • SRP signal recognition particle
  • protein synthesis is paused or slowed down.
  • the signal recognition particle carries the ribosomes to the endoplasmic reticulum, and protein synthesis restarts.
  • the newly synthesized protein enters the endoplasmic reticulum cavity, and the signal peptide sequence is removed under the action of signal peptidase.
  • termination transport sequence exists at the C-terminus of the nascent peptide chain, it may not be cleaved by signal peptidase.
  • ovalbumin contains an internal signal peptide. Neither its precursor nor its mature form is cleaved by signal peptidase.
  • binding preferably relates to specific binding.
  • specific binding refers to a binding response that determines the presence or absence of the protein in a heterogeneous population of proteins and/or other biological agents.
  • a specific ligand/antigen binds to a specific receptor/antibody and does not bind in significant amounts to other proteins present in the sample.
  • Specific binding means that the monoclonal antibody or antigen-binding fragment thereof of the present invention can specifically bind to at least two, three, four, five, six, seven, eight or more of each human target molecule. More amino acids interact.
  • the "specific binding" of an antibody is mainly characterized by two parameters: qualitative parameters (binding epitope or antibody binding position) and quantitative parameters (binding affinity or binding strength).
  • the antibody-binding epitope can be determined by FACS method, peptide spot epitope mapping method, mass spectrometry or peptide ELISA method.
  • the Biacore method and/or ELISA method can determine the binding strength of an antibody to a specific epitope.
  • the signal-to-noise ratio is often calculated as a representative measure of binding specificity. In such a signal-to-noise ratio, the signal represents the strength of the antibody binding to the target epitope, while the noise represents the strength of the antibody binding to other non-target epitopes.
  • the antibody being evaluated is considered to bind to the target epitope in a specific manner, ie, "specifically binds" when the signal-to-noise ratio for the target epitope is about 50.
  • An antigen-binding protein (including an antibody) "specifically binds” to an antigen if it binds to the antigen with a high binding affinity as determined by the affinity constant (KD) value.
  • KD affinity constant
  • the affinity constant KD is less than 10 -9 M.
  • KD refers to the affinity constant for a specific antibody-antigen interaction.
  • the term "patient” or “subject” refers to any organism to which a provided antibody, antigen-binding fragment thereof, or pharmaceutical composition is or can be administered for experimental, diagnostic, prophylactic, cosmetic and /or therapeutic purposes. Typical subjects include animals (eg, mammals such as mice, rats, rabbits, non-human primates, and/or humans). In some embodiments, the subject is a human. In some embodiments, the subject suffers from or is susceptible to one or more disorders or conditions. A patient may exhibit one or more symptoms of a disorder or condition, or may have been diagnosed with one or more disorders or conditions. In some embodiments, the patient is receiving or has received certain therapy for the diagnosis and/or treatment of such diseases, disorders or conditions.
  • animals eg, mammals such as mice, rats, rabbits, non-human primates, and/or humans.
  • the subject is a human.
  • the subject suffers from or is susceptible to one or more disorders or conditions.
  • a patient may exhibit one or more symptoms of a disorder or condition, or may have been diagnosed with one
  • treatment refers to therapeutic and preventive measures that prevent or slow down the occurrence or progression of undesirable physiological changes or conditions in a subject.
  • beneficial or desired clinical effects include, but are not limited to, alleviation of symptoms, reduction in disease severity, stabilization of disease state (i.e., no worsening), delay or slowing of disease progression, alleviation or alleviation of disease state, and partial or complete disease progression. Cure, regardless of whether the above effects are detectable. "Treatment” may also refer to prolongation of survival compared with no treatment.
  • Subjects in need of treatment include subjects who already suffer from the disease or condition, subjects who are likely to suffer from the disease or condition, or subjects who want to prevent the disease or condition.
  • prevention includes preventing or slowing the onset of the development of clinically significant disease or preventing or slowing the onset of a preclinically significant stage of disease in an at-risk individual. This includes preventive treatment of individuals at risk of developing the disease.
  • administer and “treat” or “prevent” are used to refer to an animal, human, experimental subject, cell, tissue, organ or biological fluid, it means that the exogenous drug, therapeutic agent, diagnostic agent or composition is administered to the animal Contact with , persons, subjects, cells, tissues, organs or biological fluids.
  • administering may refer to, for example, therapeutic methods, pharmacokinetic methods, diagnostic methods, research methods and experimental methods. Treating the cells includes contacting an agent with the cells and contacting the agent with a fluid, wherein the fluid is in contact with the cells.
  • administering and “treatment” also mean in vitro and ex vivo treatment of cells, for example by agents, diagnostic agents, binding compositions or by other cells.
  • the term "therapeutically effective amount” or “effective amount” refers to the amount of an antibody that binds to HBsAg of the invention when administered alone or in combination with an additional therapeutic agent to a cell, tissue, or subject.
  • a therapeutically effective dose further refers to an amount of the compound sufficient to cause alleviation of symptoms, such as treatment, cure, prevention, or alleviation of the associated medical condition, or to increase the rate of treatment, cure, prevention, or alleviation of the condition. .
  • the therapeutically effective amount refers to that ingredient alone.
  • a therapeutically effective amount refers to the combined amount of the active ingredients that produces a therapeutic effect, whether administered jointly, sequentially, or simultaneously.
  • a therapeutically effective amount will reduce symptoms usually by at least 10%; usually at least 20%; preferably at least about 30%; more preferably at least 40% and most preferably at least 50%.
  • pharmaceutically acceptable carrier includes materials that, when combined with the active ingredients of the composition, allow the ingredients to remain biologically active and not cause a destructive reaction with the subject's immune system. These carriers may include stabilizers, preservatives, salts or sugar complexes or crystals, and the like. “Pharmaceutically acceptable” refers to molecules and ingredients that do not produce allergic reactions or similar undesirable reactions when administered to humans.
  • the present invention obtains alpaca-derived heavy chain antibodies and VHH by immunizing alpacas with HBsAg antigen, and uses VHH to construct quadrivalent antibodies for the treatment and/or prevention of hepatitis B and related diseases.
  • the invention provides an IgG type tetravalent antibody that binds to hepatitis B surface antigen (HBsAg) or a subviral particle (SVP) containing HBsAg, wherein the tetravalent antibody comprises two heavy chains and two light chains, each of said heavy and light chains comprising as a variable region a VHH portion comprising CDR1, CDR2, CDR3, wherein:
  • CDR1 includes the sequence shown in SEQ ID NO: 4 or its equivalent
  • CDR2 includes the sequence shown in SEQ ID NO: 5 or its equivalent
  • CDR3 includes the sequence shown in SEQ ID NO: 6 or its equivalent. equivalent
  • CDR1 includes the sequence shown in SEQ ID NO: 11 or its equivalent
  • CDR2 includes the sequence shown in SEQ ID NO: 12 or its equivalent
  • CDR3 includes the sequence shown in SEQ ID NO: 13 or its equivalent. equivalent
  • CDR1 includes the sequence shown in SEQ ID NO: 18 or its equivalent
  • CDR2 includes the sequence shown in SEQ ID NO: 19 or its equivalent
  • CDR3 includes the sequence shown in SEQ ID NO: 20 or its equivalent. equivalent
  • CDR1 includes the sequence shown in SEQ ID NO: 25 or its equivalent
  • CDR2 includes the sequence shown in SEQ ID NO: 26 or its equivalent
  • CDR3 includes the sequence shown in SEQ ID NO: 27 or its equivalent. equivalent;
  • CDR1 includes the sequence shown in SEQ ID NO: 32 or its equivalent
  • CDR2 includes the sequence shown in SEQ ID NO: 33 or its equivalent
  • CDR3 includes the sequence shown in SEQ ID NO: 34 or its equivalent. equivalent.
  • the VHH portion comprises any or each sequence selected from SEQ ID NO: 1, SEQ ID NO: 8, SEQ ID NO: 15, SEQ ID NO: 22, and SEQ ID NO: 29 equivalent.
  • the tetravalent antibody is selected from any of the following antibodies:
  • the heavy chain includes the sequence shown in SEQ ID NO: 2 or its equivalent, and the light chain includes the sequence shown in SEQ ID NO: 3 or its equivalent;
  • the heavy chain includes the sequence shown in SEQ ID NO: 8 or its equivalent, and the light chain includes the sequence shown in SEQ ID NO: 9 or its equivalent;
  • the heavy chain includes the sequence shown in SEQ ID NO: 16 or its equivalent, and the light chain includes the sequence shown in SEQ ID NO: 17 or its equivalent;
  • the heavy chain includes the sequence shown in SEQ ID NO: 23 or its equivalent, and the light chain includes the sequence shown in SEQ ID NO: 24 or its equivalent;
  • the heavy chain includes the sequence shown in SEQ ID NO: 30 or its equivalent, and the light chain includes the sequence shown in SEQ ID NO: 31 or its equivalent.
  • the VHH portion includes CDR1, CDR2, CDR3, wherein:
  • CDR1 includes the sequence shown in SEQ ID NO: 4 or a variant thereof, which variant has a single substitution, deletion or insertion
  • CDR2 includes the sequence shown in SEQ ID NO: 5 or a variant thereof, which variant has A single substitution, deletion or insertion
  • CDR3 contains the sequence shown in SEQ ID NO: 6 or a variant thereof, which variant has a single substitution, deletion or insertion;
  • CDR1 includes the sequence shown in SEQ ID NO: 11 or a variant thereof, which variant has a single substitution, deletion or insertion
  • CDR2 includes the sequence shown in SEQ ID NO: 12 or a variant thereof, which variant has A single substitution, deletion or insertion
  • CDR3 contains the sequence shown in SEQ ID NO: 13 or a variant thereof, which variant has a single substitution, deletion or insertion;
  • CDR1 includes the sequence shown in SEQ ID NO: 18 or a variant thereof, which variant has a single substitution, deletion or insertion
  • CDR2 includes the sequence shown in SEQ ID NO: 19 or a variant thereof, which variant has A single substitution, deletion or insertion
  • CDR3 contains the sequence shown in SEQ ID NO: 20 or a variant thereof, which variant has a single substitution, deletion or insertion;
  • CDR1 includes the sequence shown in SEQ ID NO: 25 or a variant thereof, which variant has a single substitution, deletion or insertion
  • CDR2 includes the sequence shown in SEQ ID NO: 26 or a variant thereof, which variant has or
  • CDR1 includes the sequence shown in SEQ ID NO: 32 or a variant thereof, which variant has a single substitution, deletion or insertion
  • CDR2 includes the sequence shown in SEQ ID NO: 33 or a variant thereof, which variant has Single substitution, deletion or insertion
  • CDR3 contains the sequence shown in SEQ ID NO: 34 or a variant thereof, which variant has a single substitution, deletion or insertion.
  • the VHH portion comprises any or each sequence selected from SEQ ID NO: 1, SEQ ID NO: 8, SEQ ID NO: 15, SEQ ID NO: 22, and SEQ ID NO: 29 A variant that has at least 75%, 80%, or 85%, 90%, 95%, 98% or 99% sequence identity.
  • the tetravalent antibody is selected from any of the following antibodies:
  • the heavy chain includes the sequence shown in SEQ ID NO: 2 or a variant thereof, which has at least 75%, 80%, 85%, 90%, 95%, 98 % or 99% sequence identity, the light chain comprising the sequence shown in SEQ ID NO: 3 or a variant thereof having at least 75%, 80%, 85%, 90% identity with SEQ ID NO: 3 %, 95%, 98% or 99% sequence identity;
  • the heavy chain includes the sequence shown in SEQ ID NO: 8 or a variant thereof, which has at least 75%, 80%, 85%, 90%, 95%, 98 % or 99% sequence identity, the light chain comprising the sequence shown in SEQ ID NO: 9 or a variant thereof having at least 75%, 80%, 85%, 90% identity with SEQ ID NO: 9 %, 95%, 98% or 99% sequence identity;
  • the heavy chain includes the sequence shown in SEQ ID NO: 16 or a variant thereof, which has at least 75%, 80%, 85%, 90%, 95%, 98 % or 99% sequence identity, the light chain comprising the sequence shown in SEQ ID NO: 17 or a variant thereof having at least 75%, 80%, 85%, 90% identity with SEQ ID NO: 17 %, 95%, 98% or 99% sequence identity;
  • the heavy chain includes the sequence shown in SEQ ID NO: 23 or a variant thereof, which has at least 75%, 80%, 85%, 90%, 95%, 98% similarity with SEQ ID NO: 23 % or 99% sequence identity, the light chain comprising the sequence shown in SEQ ID NO: 24 or a variant thereof, which has at least 75%, 80%, 85%, 90% identity with SEQ ID NO: 24 %, 95%, 98% or 99% sequence identity; and
  • the heavy chain includes the sequence shown in SEQ ID NO: 30 or a variant thereof, which has at least 75%, 80%, 85%, 90%, 95%, 98% similarity with SEQ ID NO: 30 % or 99% sequence identity, the light chain comprising the sequence shown in SEQ ID NO: 31 or a variant thereof, which has at least 75%, 80%, 85%, 90% identity with SEQ ID NO: 31 %, 95%, 98% or 99% sequence identity.
  • the VHH portion includes CDR1, CDR2, CDR3, wherein:
  • CDR1 includes the sequence shown in SEQ ID NO: 4
  • CDR2 includes the sequence shown in SEQ ID NO: 5
  • CDR3 includes the sequence shown in SEQ ID NO: 6;
  • CDR1 includes the sequence shown in SEQ ID NO: 11
  • CDR2 includes the sequence shown in SEQ ID NO: 12
  • CDR3 includes the sequence shown in SEQ ID NO: 13;
  • CDR1 includes the sequence shown in SEQ ID NO: 18
  • CDR2 includes the sequence shown in SEQ ID NO: 19
  • CDR3 includes the sequence shown in SEQ ID NO: 20;
  • CDR1 contains the sequence shown in SEQ ID NO: 25
  • CDR2 contains the sequence shown in SEQ ID NO: 26
  • CDR3 contains the sequence shown in SEQ ID NO: 27;
  • CDR1 includes the sequence shown in SEQ ID NO: 32
  • CDR2 includes the sequence shown in SEQ ID NO: 33
  • CDR3 includes the sequence shown in SEQ ID NO: 34.
  • the VHH portion includes CDR1, CDR2, CDR3, wherein:
  • CDR1 is the sequence shown in SEQ ID NO: 4
  • CDR2 is the sequence shown in SEQ ID NO: 5
  • CDR3 is the sequence shown in SEQ ID NO: 6;
  • CDR1 is the sequence shown in SEQ ID NO: 11
  • CDR2 is the sequence shown in SEQ ID NO: 12
  • CDR3 is the sequence shown in SEQ ID NO: 13;
  • CDR1 is the sequence shown in SEQ ID NO: 18
  • CDR2 is the sequence shown in SEQ ID NO: 19
  • CDR3 is the sequence shown in SEQ ID NO: 20;
  • CDR1 is the sequence shown in SEQ ID NO: 25
  • CDR2 is the sequence shown in SEQ ID NO: 26
  • CDR3 is the sequence shown in SEQ ID NO: 27;
  • CDR1 is the sequence shown in SEQ ID NO: 32
  • CDR2 is the sequence shown in SEQ ID NO: 33
  • CDR3 is the sequence shown in SEQ ID NO: 34.
  • the VHH portion includes any sequence selected from SEQ ID NO: 1, SEQ ID NO: 8, SEQ ID NO: 15, SEQ ID NO: 22, and SEQ ID NO: 29.
  • the tetravalent antibody is selected from any of the following antibodies:
  • the heavy chain includes the sequence shown in SEQ ID NO: 2, and the light chain includes the sequence shown in SEQ ID NO: 3;
  • the heavy chain includes the sequence shown in SEQ ID NO: 8, and the light chain includes the sequence shown in SEQ ID NO: 9;
  • the heavy chain includes the sequence shown in SEQ ID NO: 16, and the light chain includes the sequence shown in SEQ ID NO: 17;
  • the heavy chain includes the sequence shown in SEQ ID NO: 23, and the light chain includes the sequence shown in SEQ ID NO: 24;
  • the heavy chain includes the sequence shown in SEQ ID NO: 30, and the light chain includes the sequence shown in SEQ ID NO: 31.
  • any of the above antibodies is of the IgG type, such as IgGl, IgG2, IgG3 or IgG4 type. In some embodiments, any of the above-described antibodies is of the IgG1 type.
  • the invention provides a heavy chain antibody that binds to hepatitis B surface antigen (HBsAg) or a subviral particle (SVP) comprising HBsAg, wherein the heavy chain antibody comprises as a heavy chain variable
  • HBsAg hepatitis B surface antigen
  • SVP subviral particle
  • CDR1 includes the sequence shown in SEQ ID NO: 4 or its equivalent
  • CDR2 includes the sequence shown in SEQ ID NO: 5 or its equivalent
  • CDR3 includes the sequence shown in SEQ ID NO: 6 or its equivalent. equivalent
  • CDR1 includes the sequence shown in SEQ ID NO: 11 or its equivalent
  • CDR2 includes the sequence shown in SEQ ID NO: 12 or its equivalent
  • CDR3 includes the sequence shown in SEQ ID NO: 13 or its equivalent. equivalent
  • CDR1 includes the sequence shown in SEQ ID NO: 18 or its equivalent
  • CDR2 includes the sequence shown in SEQ ID NO: 19 or its equivalent
  • CDR3 includes the sequence shown in SEQ ID NO: 20 or its equivalent. equivalent
  • CDR1 includes the sequence shown in SEQ ID NO: 25 or its equivalent
  • CDR2 includes the sequence shown in SEQ ID NO: 26 or its equivalent
  • CDR3 includes the sequence shown in SEQ ID NO: 27 or its equivalent. equivalent;
  • CDR1 includes the sequence shown in SEQ ID NO: 32 or its equivalent
  • CDR2 includes the sequence shown in SEQ ID NO: 33 or its equivalent
  • CDR3 includes the sequence shown in SEQ ID NO: 34 or its equivalent. equivalent.
  • the VHH portion comprises any or each sequence selected from SEQ ID NO: 1, SEQ ID NO: 8, SEQ ID NO: 15, SEQ ID NO: 22, and SEQ ID NO: 29 equivalent.
  • the heavy chain antibody comprises a VHH portion comprising CDR1, CDR2, CDR3, wherein:
  • CDR1 includes the sequence shown in SEQ ID NO: 4 or a variant thereof, which variant has a single substitution, deletion or insertion
  • CDR2 includes the sequence shown in SEQ ID NO: 5 or a variant thereof, which variant has A single substitution, deletion or insertion
  • CDR3 contains the sequence shown in SEQ ID NO: 6 or a variant thereof, which variant has a single substitution, deletion or insertion;
  • CDR1 includes the sequence shown in SEQ ID NO: 11 or a variant thereof, which variant has a single substitution, deletion or insertion
  • CDR2 includes the sequence shown in SEQ ID NO: 12 or a variant thereof, which variant has A single substitution, deletion or insertion
  • CDR3 contains the sequence shown in SEQ ID NO: 13 or a variant thereof, which variant has a single substitution, deletion or insertion;
  • CDR1 includes the sequence shown in SEQ ID NO: 18 or a variant thereof, which variant has a single substitution, deletion or insertion
  • CDR2 includes the sequence shown in SEQ ID NO: 19 or a variant thereof, which variant has A single substitution, deletion or insertion
  • CDR3 contains the sequence shown in SEQ ID NO: 20 or a variant thereof, which variant has a single substitution, deletion or insertion;
  • CDR1 includes the sequence shown in SEQ ID NO: 25 or a variant thereof, which variant has a single substitution, deletion or insertion
  • CDR2 includes the sequence shown in SEQ ID NO: 26 or a variant thereof, which variant has or
  • CDR1 includes the sequence shown in SEQ ID NO: 32 or a variant thereof, which variant has a single substitution, deletion or insertion
  • CDR2 includes the sequence shown in SEQ ID NO: 33 or a variant thereof, which variant has Single substitution, deletion or insertion
  • CDR3 contains the sequence shown in SEQ ID NO: 34 or a variant thereof, which variant has a single substitution, deletion or insertion.
  • the VHH portion comprises any or each sequence selected from SEQ ID NO: 1, SEQ ID NO: 8, SEQ ID NO: 15, SEQ ID NO: 22, and SEQ ID NO: 29 A variant that has at least 75%, 80%, or 85%, 90%, 95%, 98% or 99% sequence identity.
  • the heavy chain antibody comprises a VHH portion comprising CDR1, CDR2, CDR3, wherein:
  • CDR1 includes the sequence shown in SEQ ID NO: 4
  • CDR2 includes the sequence shown in SEQ ID NO: 5
  • CDR3 includes the sequence shown in SEQ ID NO: 6;
  • CDR1 includes the sequence shown in SEQ ID NO: 11
  • CDR2 includes the sequence shown in SEQ ID NO: 12
  • CDR3 includes the sequence shown in SEQ ID NO: 13;
  • CDR1 includes the sequence shown in SEQ ID NO: 18
  • CDR2 includes the sequence shown in SEQ ID NO: 19
  • CDR3 includes the sequence shown in SEQ ID NO: 20;
  • CDR1 contains the sequence shown in SEQ ID NO: 25
  • CDR2 contains the sequence shown in SEQ ID NO: 26
  • CDR3 contains the sequence shown in SEQ ID NO: 27;
  • CDR1 includes the sequence shown in SEQ ID NO: 32
  • CDR2 includes the sequence shown in SEQ ID NO: 33
  • CDR3 includes the sequence shown in SEQ ID NO: 34.
  • the heavy chain antibody comprises a VHH portion comprising CDR1, CDR2, CDR3, wherein:
  • CDR1 is the sequence shown in SEQ ID NO: 4
  • CDR2 is the sequence shown in SEQ ID NO: 5
  • CDR3 is the sequence shown in SEQ ID NO: 6;
  • CDR1 is the sequence shown in SEQ ID NO: 11
  • CDR2 is the sequence shown in SEQ ID NO: 12
  • CDR3 is the sequence shown in SEQ ID NO: 13;
  • CDR1 is the sequence shown in SEQ ID NO: 18
  • CDR2 is the sequence shown in SEQ ID NO: 19
  • CDR3 is the sequence shown in SEQ ID NO: 20;
  • CDR1 is the sequence shown in SEQ ID NO: 25
  • CDR2 is the sequence shown in SEQ ID NO: 26
  • CDR3 is the sequence shown in SEQ ID NO: 27;
  • CDR1 is the sequence shown in SEQ ID NO: 32
  • CDR2 is the sequence shown in SEQ ID NO: 33
  • CDR3 is the sequence shown in SEQ ID NO: 34.
  • the VHH portion includes any sequence selected from SEQ ID NO: 1, SEQ ID NO: 8, SEQ ID NO: 15, SEQ ID NO: 22, and SEQ ID NO: 29.
  • the CDR1, CDR1 and CDR3 are defined based on any one of IMGT, Kabat, Chothia, Contact or Martin definition schemes. In some embodiments, the CDR1, CDR1 and CDR3 are defined based on the IMGT definition scheme.
  • substitutions described herein are conservative substitutions.
  • Constant (amino acid) substitution refers to a substitution in which an amino acid residue is replaced with an amino acid having a similar side chain.
  • Families of amino acid residues with similar side chains have been defined in the art and include basic side chains (e.g., lysine, arginine, histidine), acidic side chains (e.g., aspartic acid, glutamic acid) , uncharged polar side chains (such as glycine, asparagine, glutamine, serine, threonine, tyrosine, cysteine), non-polar side chains (such as alanine, valine acid, leucine, isoleucine, proline, phenylalanine, methionine, tryptophan), ⁇ -branched side chains (e.g., threonine, valine, isoleucine ) and aromatic side chains (e.g.
  • a non-essential amino acid residue in an immunoglobulin polypeptide is preferably replaced by another amino acid residue from the same side chain family.
  • a string of amino acids can be substituted with a structurally similar string that differs in the order and/or composition of the side chain family members.
  • antibodies disclosed herein can be modified so that their amino acid sequences differ from the naturally occurring binding polypeptides from which they are derived.
  • a polypeptide or amino acid sequence derived from a given protein may be similar to the starting sequence, e.g., have a certain percentage of identity, e.g., it may be 60%, 70%, 75%, 80%, 85%, 90%, 95 %, 98%, 99%, or a range between any two of these values is the same as the starting sequence.
  • antibodies comprise an amino acid sequence or one or more portions not typically associated with antibodies. Exemplary modifications are described in greater detail herein.
  • the antibodies disclosed herein can include flexible linker sequences, or can be modified to add functional moieties (eg, polyethylene glycol (PEG), drugs, toxins, or labels).
  • functional moieties eg, polyethylene glycol (PEG), drugs, toxins, or labels.
  • the antibodies, variants or derivatives thereof of the present invention include derivatives that are modified, ie, by covalent attachment of any type of molecule to the antibody, such that the covalent attachment does not prevent the antibody from binding to the epitope.
  • antibodies can be modified, for example, by glycosylation, acetylation, PEGylation, phosphorylation, amidation, derivatization by known protecting/blocking groups, proteolysis Cleavage, attachment to cellular ligands or other proteins, etc. Any of a variety of chemical modifications can be performed by known techniques, including but not limited to specific chemical cleavage, acetylation, formylation, metabolic synthesis of tunicamycin, and the like. Additionally, antibodies may contain one or more non-canonical amino acids.
  • the antibody can be conjugated to a therapeutic agent, prodrug, peptide, protein, enzyme, virus, lipid, biological response modifier, pharmaceutical agent, or PEG.
  • Antibodies can be conjugated or fused to therapeutic agents, which can include detectable labels (e.g., radioactive labels), immunomodulators, hormones, enzymes, oligonucleotides, photoactive therapeutic or diagnostic agents, cytotoxic agents (which can be drugs or toxins), ultrasound enhancers, non-radioactive labels, combinations thereof, and other such agents known in the art.
  • detectable labels e.g., radioactive labels
  • immunomodulators e.g., hormones, enzymes, oligonucleotides, photoactive therapeutic or diagnostic agents, cytotoxic agents (which can be drugs or toxins), ultrasound enhancers, non-radioactive labels, combinations thereof, and other such agents known in the art.
  • Antibodies can be detectably labeled by conjugating them to chemiluminescent compounds. The presence of the chemiluminescently labeled antigen-binding polypeptide is then determined by detecting the presence of luminescence that occurs during the chemical reaction.
  • chemiluminescent labeling compounds are luminol, isoluminol, thermostable acridinium esters, imidazole, acridinium salts and oxalate esters.
  • Antibodies can also be detectably labeled using fluorescent emitting metals such as Eu or other metals of the lanthanide series. These metals can be attached to the antibody using metal chelating groups such as diethylenetriaminepentaacetic acid (DTPA) or ethylenediaminetetraacetic acid (EDTA). Techniques for conjugating various moieties to antibodies are well known.
  • fluorescent emitting metals such as Eu or other metals of the lanthanide series.
  • metals can be attached to the antibody using metal chelating groups such as diethylenetriaminepentaacetic acid (DTPA) or ethylenediaminetetraacetic acid (EDTA). Techniques for conjugating various moieties to antibodies are well known.
  • DTPA diethylenetriaminepentaacetic acid
  • EDTA ethylenediaminetetraacetic acid
  • the tetravalent antibody or heavy chain antibody is preferably a humanized antibody or a chimeric antibody.
  • Humanized antibodies are antibody molecules derived from antibodies of a non-human species that bind a desired antigen having one or more complementarity determining regions (CDRs) from the non-human species and framework regions from a human immunoglobulin molecule.
  • CDRs complementarity determining regions
  • framework residues in the human framework regions will be substituted with corresponding residues from the CDR donor antibody to alter, preferably improve, antigen binding.
  • These framework substitutions are identified by methods well known in the art, for example, by modeling the interactions of CDR and framework residues to identify framework residues important for antigen binding and sequence comparison to identify unusual framework residues at specific positions. base.
  • Antibodies can be humanized using a variety of techniques known in the art, including, for example, CDR-grafting, veneering or resurfacing and chain shuffling.
  • Fully human antibodies are particularly ideal for therapeutic treatment of human patients.
  • Human antibodies can be prepared by a variety of methods known in the art, including phage display methods using antibody libraries derived from human immunoglobulin sequences.
  • Human antibodies can also be produced using transgenic mice that are unable to express functional endogenous immunoglobulins but that express human immunoglobulin genes.
  • human heavy and light chain immunoglobulin gene complexes can be introduced into mouse embryonic stem cells either randomly or by homologous recombination.
  • human variable, constant and diversity regions can be introduced into mouse embryonic stem cells.
  • Mouse heavy chain and light chain immunoglobulin genes can be rendered functional separately or simultaneously upon introduction of human immunoglobulin loci via homologous recombination. In particular, homozygous deletion of the JH region prevents endogenous antibody production. Modified embryonic stem cells were expanded and microinjected into blastocysts to generate chimeric mice.
  • Transgenic mice are immunized in the normal manner with a selected antigen, eg, all or part of the desired target polypeptide. Monoclonal antibodies against antigens can be obtained from immunized transgenic mice using conventional hybridoma technology. Transgenic mice carry human immunoglobulin transgenes that rearrange during B cell differentiation and subsequently undergo class switching and somatic mutations. Therefore, using this technology, it is possible to generate therapeutically useful IgG, IgA, IgM and IgE antibodies.
  • Fully human antibodies that recognize selected epitopes can also be generated using a technique called "guided selection.”
  • a non-human monoclonal antibody such as a mouse antibody, is selected to guide the selection of fully human antibodies that recognize the same epitope.
  • the DNA encoding the desired monoclonal antibody can be readily isolated and sequenced using routine procedures (eg, by using oligonucleotide probes capable of binding specifically to the genes encoding the murine antibody heavy and light chains). Isolated and subcloned hybridoma cells serve as a preferred source of such DNA. Once isolated, the DNA can be placed in an expression vector and then transfected into prokaryotic or eukaryotic host cells, such as E. coli cells, simian COS cells, Chinese hamster ovary (CHO) cells, or bone marrow that does not produce immunoglobulins. tumor cells. More specifically, the isolated DNA can be used to clone constant and variable region sequences for use in making antibodies.
  • prokaryotic or eukaryotic host cells such as E. coli cells, simian COS cells, Chinese hamster ovary (CHO) cells, or bone marrow that does not produce immunoglobulins. tumor cells. More specifically, the isolated DNA can be used to
  • RNA to be extracted from selected cells, converted to cDNA, and amplified by PCR using Ig-specific primers.
  • transformed cells expressing the desired antibodies can be grown in relatively large quantities to provide clinical and commercial supplies of immunoglobulins.
  • one or more CDRs of an antigen-binding polypeptide of the present disclosure can be inserted into a framework region using conventional recombinant DNA techniques, for example, into a human framework region to humanize a non-human antibody.
  • the framework regions may be naturally occurring or consensus framework regions, and are preferably human framework regions.
  • the polynucleotide generated from the combination of framework regions and CDRs encodes an antibody that specifically binds to at least one epitope of the desired polypeptide (eg, LIGHT).
  • one or more amino acid substitutions may be made within the framework region, and preferably the amino acid substitutions increase the binding of the antibody to its antigen.
  • a chimeric antibody is a molecule in which different portions are derived from different animal species, such as a molecule having a variable region derived from a murine monoclonal antibody and a human immunoglobulin constant region.
  • Another highly efficient method for generating recombinant antibodies results in the generation of primate antibodies containing monkey variable domains and human constant sequences.
  • humanizing the polypeptide according to the present invention involves using one or more camelid amino acids with their human counterparts found in the human consensus sequence substitution without the polypeptide losing its typical characteristics, that is, the humanization does not significantly affect the antigen-binding ability of the resulting polypeptide. This method is well known to the skilled person.
  • "humanization" of a VHH refers to the replacement of one or more amino acid residues in the amino acid sequence (and specifically in the framework sequence) of a naturally occurring VHH sequence with conventional 4 amino acid residues from human One or more amino acid residues present at corresponding positions in the VH domain of the chain antibody. This can be done using humanization techniques known in the art. In some embodiments, possible humanizing substitutions or combinations of humanizing substitutions can be determined by methods known in the art, for example, by comparing the sequence of a VHH with the sequence of a naturally occurring human VH domain. Compare. In some embodiments, the humanizing substitutions are selected such that the resulting humanized VHH retains advantageous functional properties.
  • the VHH of the present application can become more "human-like" compared to the corresponding naturally occurring VHH domain, while still retaining advantageous properties, such as reduced immunogenicity.
  • the humanized VHH of the present application can be obtained by any suitable means known in the art, and is therefore not strictly limited to those that have been obtained using a polypeptide comprising a naturally occurring VHH domain as a starting material. Peptides.
  • "humanization” and “camelization” can be performed by providing a nucleotide sequence encoding a naturally occurring VHH domain or VH domain, respectively, and then using a method known in the art to One or more codons in the nucleotide sequence are altered in such a way that the new nucleotide sequence encodes a "humanized” or “camelized” VHH, respectively.
  • This nucleic acid can then be expressed in a manner known in the art to provide the desired VHH of the present application.
  • the amino acid sequence of the desired humanized or camelized VHH of the present application can be designed based on the amino acid sequence of the naturally occurring VHH domain or VH domain, respectively, and then synthesized using peptides known in the art Technology synthesized from scratch. Furthermore, based on the amino acid sequence or nucleotide sequence of the naturally occurring VHH domain or VH domain, respectively, a nucleotide sequence encoding the desired humanized or camelized VHH can be designed, and then used as known in the art. The nucleic acid synthesis technology is de novo synthesized, and the nucleic acid thus obtained can thereafter be expressed in a manner known in the art to provide the desired VHH of the present application.
  • VHHs of the present application and/or nucleic acids encoding them starting from naturally occurring VH sequences or VHH sequences are known in the art and may, for example, include combinations in a suitable manner
  • One or more portions of one or more naturally occurring VH sequences e.g., one or more FR sequences and/or CDR sequences
  • one or more portions of one or more naturally occurring VHH sequences e.g., a or multiple FR sequences or CDR sequences
  • synthetic or semi-synthetic sequences to provide the VHH of the present application or the nucleotide sequence or nucleic acid encoding it.
  • the present invention provides a humanized IgG type tetravalent antibody that binds to hepatitis B surface antigen (HBsAg) or HBsAg-containing subviral particles (SVP), wherein the tetravalent antibody includes two heavy chains and two light chains, each of said heavy and light chains comprising as a variable region a VHH portion comprising CDR1, CDR2, CDR3, wherein:
  • CDR1 includes the sequence shown in SEQ ID NO: 4 or its equivalent
  • CDR2 includes the sequence shown in SEQ ID NO: 5 or its equivalent
  • CDR3 includes the sequence shown in SEQ ID NO: 6 or its equivalent. equivalent
  • CDR1 includes the sequence shown in SEQ ID NO: 11 or its equivalent
  • CDR2 includes the sequence shown in SEQ ID NO: 12 or its equivalent
  • CDR3 includes the sequence shown in SEQ ID NO: 13 or its equivalent. equivalent
  • CDR1 includes the sequence shown in SEQ ID NO: 18 or its equivalent
  • CDR2 includes the sequence shown in SEQ ID NO: 19 or its equivalent
  • CDR3 includes the sequence shown in SEQ ID NO: 20 or its equivalent. equivalent
  • CDR1 includes the sequence shown in SEQ ID NO: 25 or its equivalent
  • CDR2 includes the sequence shown in SEQ ID NO: 26 or its equivalent
  • CDR3 includes the sequence shown in SEQ ID NO: 27 or its equivalent. equivalent;
  • CDR1 includes the sequence shown in SEQ ID NO: 32 or its equivalent
  • CDR2 includes the sequence shown in SEQ ID NO: 33 or its equivalent
  • CDR3 includes the sequence shown in SEQ ID NO: 34 or its equivalent. equivalent.
  • the present invention provides humanized heavy chain antibodies that bind to hepatitis B surface antigen (HBsAg) or subviral particles (SVP) containing HBsAg, wherein the heavy chain antibodies comprise VHH as the heavy chain variable region part, the VHH part includes CDR1, CDR2, CDR3, where:
  • CDR1 includes the sequence shown in SEQ ID NO: 4 or its equivalent
  • CDR2 includes the sequence shown in SEQ ID NO: 5 or its equivalent
  • CDR3 includes the sequence shown in SEQ ID NO: 6 or its equivalent. equivalent
  • CDR1 includes the sequence shown in SEQ ID NO: 11 or its equivalent
  • CDR2 includes the sequence shown in SEQ ID NO: 12 or its equivalent
  • CDR3 includes the sequence shown in SEQ ID NO: 13 or its equivalent. equivalent
  • CDR1 includes the sequence shown in SEQ ID NO: 18 or its equivalent
  • CDR2 includes the sequence shown in SEQ ID NO: 19 or its equivalent
  • CDR3 includes the sequence shown in SEQ ID NO: 20 or its equivalent. equivalent
  • CDR1 includes the sequence shown in SEQ ID NO: 25 or its equivalent
  • CDR2 includes the sequence shown in SEQ ID NO: 26 or its equivalent
  • CDR3 includes the sequence shown in SEQ ID NO: 27 or its equivalent. equivalent;
  • CDR1 includes the sequence shown in SEQ ID NO: 32 or its equivalent
  • CDR2 includes the sequence shown in SEQ ID NO: 33 or its equivalent
  • CDR3 includes the sequence shown in SEQ ID NO: 34 or its equivalent. equivalent.
  • the present invention provides a chimeric IgG type tetravalent antibody that binds to hepatitis B surface antigen (HBsAg) or HBsAg-containing subviral particles (SVP), wherein the tetravalent antibody includes two heavy chains and Two light chains, each of the heavy chain and the light chain comprising as a variable region a VHH portion comprising a portion selected from the group consisting of SEQ ID NO: 1, SEQ ID NO: 8, SEQ ID NO: 15 , any sequence of SEQ ID NO: 22 and SEQ ID NO: 29 or the equivalent of each thereof.
  • HBsAg hepatitis B surface antigen
  • SVP subviral particles
  • the present invention provides a chimeric heavy chain antibody that binds to hepatitis B surface antigen (HBsAg) or a subviral particle (SVP) containing HBsAg, wherein the heavy chain antibody comprises as a heavy chain variable region A VHH portion comprising any sequence selected from the group consisting of SEQ ID NO: 1, SEQ ID NO: 8, SEQ ID NO: 15, SEQ ID NO: 22, and SEQ ID NO: 29, or the equivalent of each of them things.
  • HBsAg hepatitis B surface antigen
  • SVP subviral particle
  • the above-mentioned humanized or chimeric tetravalent antibody may comprise a heavy chain constant region and a light chain constant region
  • the humanized or chimeric heavy chain antibody may comprise a heavy chain constant region, which is, for example, SEQ ID NO:
  • the human IgG1 heavy chain constant region shown in 38, the light chain constant region is, for example, the human Ig ⁇ light chain constant region shown in SEQ ID NO: 39.
  • the invention provides a nucleotide sequence comprising a polynucleotide encoding an antibody of any of the above aspects.
  • the polynucleotide comprises any sequence selected from SEQ ID NO: 7, SEQ ID NO: 14, SEQ ID NO: 21, SEQ ID NO: 28, and SEQ ID NO: 35, or each sequence thereof. The equivalent of a.
  • One aspect of the invention provides a method of treating and/or preventing hepatitis B, the method comprising administering to a subject a therapeutically effective amount of any one of the above antibodies.
  • Another aspect of the invention provides a method of preventing diseases caused by hepatitis B, the method comprising administering to a subject a therapeutically effective amount of any one of the above antibodies.
  • another aspect of the present invention provides the use of any one of the above antibodies in the preparation of a medicament for the treatment and/or prevention of hepatitis B.
  • Another aspect of the present invention provides the use of any one of the above antibodies in the preparation of a medicament for preventing diseases caused by hepatitis B.
  • another aspect of the present invention provides any of the above antibodies for use in the treatment and/or prevention of hepatitis B.
  • Another aspect of the present invention provides any of the above antibodies for use in preventing diseases caused by hepatitis B.
  • the hepatitis B is chronic hepatitis B.
  • the disease caused by hepatitis B is cirrhosis, liver failure or hepatocellular carcinoma caused by hepatitis B.
  • Suitable routes of administration include parenteral (eg, intramuscular, intravenous or subcutaneous) and oral administration.
  • Other conventional modes of administration include administration via tracheal intubation, oral ingestion, inhalation, topical application, or transdermal, subcutaneous, intraperitoneal, or intraarterial injection.
  • Appropriate dosages are determined by the clinician based on parameters or factors known or suspected in the art to affect treatment or expected to affect treatment. Typically, the dose is started slightly lower than the optimal dose and is increased by small amounts until the desired or optimal effect relative to any adverse side effects is achieved.
  • Important monitoring indicators include measuring, for example, inflammatory symptoms or the levels of inflammatory cytokines produced.
  • One aspect of the present invention provides a pharmaceutical composition, which includes a therapeutically effective amount of any one of the above antibodies, and a pharmaceutically acceptable carrier.
  • the pharmaceutical composition is used to treat and/or prevent hepatitis B, such as chronic hepatitis B.
  • the pharmaceutical composition is used to prevent diseases caused by hepatitis B, such as cirrhosis, liver failure, or hepatocellular carcinoma caused by hepatitis B.
  • a pharmaceutical or sterile composition the drug is mixed with a pharmaceutically acceptable carrier or excipient.
  • a pharmaceutically acceptable carrier or excipient in the form of, for example, lyophilized powders, slurries, aqueous solutions or suspensions can be prepared by mixing with physiologically acceptable carriers, excipients or stabilizers.
  • Pharmaceutically acceptable carriers are well known in the art. It is known in the art how to prepare aqueous compositions containing as active ingredient. Typically, these compositions are prepared as injectables or sprays, such as liquid solutions or suspensions; solid forms suitable for solution or suspension prior to injection or spraying may also be prepared.
  • HBV heavy chain antibodies from alpacas immunized with HBsAg.
  • the screened antibodies are then confirmed using Elisa, and the antibodies are sequenced to confirm their VHH portion.
  • Figure 1 is a schematic structural comparison of the antibody constructed as above and a conventional control antibody.
  • the antibody constructed in this example has a generally similar structure to the conventional IgG1 antibody, both consisting of two heavy chains and two light chains. The difference lies in the light chain variable region and heavy chain corresponding to the conventional antibody.
  • the antibody of the present invention has a VHH portion, thereby having 4 identical VHH portions on a single antibody molecule, forming a quadrivalent antibody.
  • the sequences of the five antibodies C1, C2, C3, C4, C5 and the control RH antibody constructed in this example can be found in the "Sequence Listing" section above.
  • the control antibody RH is Rachel Eren et al. in Preclinical Evaluation of Two Human Anti-Hepatitis B Virus(HBV)Monoclonal Antibodies in the HBV-Trimera Mouse Model and in HBV Chronic Carrier Chimpanzees.Hepatology, 2000, 32(3): 588-596
  • the antibody 17.1.41 disclosed in is used in subsequent examples of this application.
  • Example 2 Binding activity of the antibody of the present invention to HBsAg
  • ELISA test The ELISA method was performed to determine the interaction between the antibody constructed in Example 1 and HBsAg. Briefly, plates were coated with 0.5ug/ml HBsAg. Block and then add different concentrations of antibodies. Wash, then add secondary antibody with HRP. The plate was read at 420 nm after adding TMB substrate. The detection principle is shown in Figure 2.
  • Example 3 Effect of the antibody of the present invention on HBsAg aggregation
  • the kit used in this example is Antu Bio's HBsAg ELISA kit.
  • Direct HBsAg ELISA test A direct HBsAg ELISA method was performed to determine the effect of the antibodies constructed in Example 1 on HBsAg aggregation. Briefly, plates were coated with HBsAg. Block and then add different concentrations of antibodies. Wash, then add HBsAg with HRP. The plate was read at 420 nm after adding TMB substrate. The detection principle is shown in Figure 3.
  • the readings of antibodies C1, C2 and C5 are significantly lower, indicating that the VHH-based IgG antibodies constructed in the present invention will not continue to bind to other HBsAg after binding to HBsAg, and will not cause the aggregation of HBsAg aggregates.
  • the results of this experiment show that the VHH-based IgG antibody constructed in the present invention only binds to a single SVP and does not cause cross-linking and aggregation of SVP, allowing macrophages and the like to perform phagocytosis against a single SVP and clear the aggregates.
  • Example 4 HDI-HBV model testing the in vivo activity of the antibody of the present invention
  • HBV plasmid Prepare HBV plasmid according to general procedures. Check DNA quality and concentration via NanoDrop. The A260/A280 ratio of high-quality plasmid DNA should be ⁇ 1.8. It is important that the purified plasmid DNA is of high quality and free of proteins, endotoxins, DNase, and RNase to prevent adverse or toxic effects on the animal.
  • mice Measure the body weight of mice. Prepare 10 ⁇ g of HBV plasmid DNA and dissolve it in PBS equivalent to 8% of the mouse body weight.
  • a safe and effective heat source such as a heating lamp (120W bulb)
  • a heating lamp 120W bulb
  • This step helps visualize the tail vein and ensures optimal injection. As the mouse's tail warms, the veins should dilate and become more visible. Keep mice warm before hydrodynamic injection.
  • mice were anesthetized by intramuscular injection using Imalgene (ketamine, 60 mg/kg) and Rompun TM (xylazine, 12 mg/kg). Immobilize the mouse with a restraint device before hydrodynamic injection. While working under a light source, position the dilated vein on the ventral side of the mouse's tail, preferably near the distal (tip) end of the tail. Wipe the area with an alcohol pad and allow it to air dry to further increase vein visibility and disinfect the injection site.
  • Imalgene ketamine, 60 mg/kg
  • Rompun TM xylazine, 12 mg/kg
  • mice generally tolerate hydrodynamic injections well, but may remain motionless and exhibit dyspnea lasting approximately 5 minutes immediately following injection.
  • the observed apnea may be due to a vasovagal response induced by rapid administration of large amounts of HBV DNA solution.
  • Gently massaging the mouse's chest is enough to stimulate breathing and promote recovery.
  • the heart rate may slow or increase rapidly during the first minutes after the injection, but this should normalize.
  • Mice should recover within 5 minutes of injection. If a mouse appears to have seizures after an injection, this may indicate that air bubbles or impurities have entered the circulatory system and the mouse may not survive. Careful monitoring of mice after injection is necessary.
  • the GTA/GTD HDI model C57BL/6 male mice treated by the above method were administered on day 0 and collected on days 1, 2, 3, 5, 7, 10 and 14 Serum was analyzed. Measure HBsAg in blood using the HBsAg Direct ELISA kit.
  • the antibody constructed in Example 1 can effectively reduce HBsAg in vivo.
  • the C5 antibody can significantly reduce HBsAg at a concentration of 0.3 mg/kg until the third day after administration, and at a concentration of 3 mg/kg, it can significantly reduce HBsAg until the fifth day after administration.
  • C3 antibody appears to have the best effect, and can significantly reduce HBsAg at a concentration of 0.3mg/kg until the 7th day after administration.

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Organic Chemistry (AREA)
  • Genetics & Genomics (AREA)
  • General Health & Medical Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Medicinal Chemistry (AREA)
  • Biotechnology (AREA)
  • Zoology (AREA)
  • Wood Science & Technology (AREA)
  • Biomedical Technology (AREA)
  • Virology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Molecular Biology (AREA)
  • Biochemistry (AREA)
  • Microbiology (AREA)
  • General Engineering & Computer Science (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Immunology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Biophysics (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Communicable Diseases (AREA)
  • Cell Biology (AREA)
  • Epidemiology (AREA)
  • Mycology (AREA)
  • Oncology (AREA)
  • Physics & Mathematics (AREA)
  • Plant Pathology (AREA)
  • Peptides Or Proteins (AREA)

Abstract

La présente invention concerne un anticorps anti-HBsAg. En particulier, la présente invention concerne un anticorps tétravalent lié à HBsAg et un anticorps à chaîne lourde correspondant. La présente invention concerne en outre une composition pharmaceutique comprenant les anticorps, ainsi que son utilisation médicale. Les anticorps de la présente invention ont une haute force de liaison avec le HBsAg, ne provoquent pas la formation d'agrégats de HBsAg, peuvent réduire efficacement le niveau de HBsAg in vivo, et peuvent être utilisés pour traiter et/ou prévenir des maladies associées à l'hépatite B.
PCT/CN2023/096996 2022-05-31 2023-05-30 Anticorps anti-hbsag et son utilisation Ceased WO2023232003A1 (fr)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
CN202210612698 2022-05-31
CN202210612698.7 2022-05-31

Publications (1)

Publication Number Publication Date
WO2023232003A1 true WO2023232003A1 (fr) 2023-12-07

Family

ID=89026919

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/CN2023/096996 Ceased WO2023232003A1 (fr) 2022-05-31 2023-05-30 Anticorps anti-hbsag et son utilisation

Country Status (1)

Country Link
WO (1) WO2023232003A1 (fr)

Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN109160948A (zh) * 2018-09-21 2019-01-08 成都阿帕克生物科技有限公司 一种乙肝表面抗原纳米抗体及核酸分子和应用
CN112165974A (zh) * 2018-05-31 2021-01-01 诺华股份有限公司 乙型肝炎抗体
WO2021168575A1 (fr) * 2020-02-27 2021-09-02 Quadrumix Biotechnology Inc. Polypeptides dirigés contre une infection virale et leurs utilisations
CN113912706A (zh) * 2020-07-09 2022-01-11 北京凯因科技股份有限公司 结合乙型肝炎病毒表面抗原的抗体及其应用

Patent Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN112165974A (zh) * 2018-05-31 2021-01-01 诺华股份有限公司 乙型肝炎抗体
CN109160948A (zh) * 2018-09-21 2019-01-08 成都阿帕克生物科技有限公司 一种乙肝表面抗原纳米抗体及核酸分子和应用
WO2021168575A1 (fr) * 2020-02-27 2021-09-02 Quadrumix Biotechnology Inc. Polypeptides dirigés contre une infection virale et leurs utilisations
CN113912706A (zh) * 2020-07-09 2022-01-11 北京凯因科技股份有限公司 结合乙型肝炎病毒表面抗原的抗体及其应用

Similar Documents

Publication Publication Date Title
ES3009462T3 (en) Method of treating or ameliorating metabolic disorders using glp-1 receptor agonists conjugated to antagonists for gastric inhibitory peptide receptor (gipr)
JP2024097078A (ja) Ｂ型肝炎ウイルスを強力に中和する抗体及びその使用
JP2022101631A (ja) 抗ｐｄ‐ｌ１抗体とｉｌ‐７との融合
BR112019021182A2 (pt) Agentes de anticorpo anti-cd33
US12497447B2 (en) Anti-GDF15 antibody and a dosage regimen for the treatment of cancer
CN110092837B (zh) Uti融合蛋白
CN105934249A (zh) 用于治疗肺高压的组合物和方法
JP2018104436A (ja) 補体活性化を検出するための組成物および方法
JP2025108529A (ja) 抗ｃｄ７９抗体およびその使用
WO2018184593A1 (fr) Anticorps pour traiter une infection par l'hépatite b et maladie associée
KR20090067214A (ko) 순차적 병용 요법
CN113637070A (zh) 抗spike蛋白的抗体或抗原结合片段及其应用
JP2022501319A (ja) 抗Ｓｉｇｌｅｃ抗体、それを備える薬学的組成物及びその使用
JP2010521139A5 (fr)
WO2023143445A1 (fr) Peptide épitope et anticorps pour traiter une infection par vhb et des maladies associées
WO2023232003A1 (fr) Anticorps anti-hbsag et son utilisation
WO2021070883A1 (fr) Anticorps de liaison au ntcp humain pouvant inhiber l'infection par le virus de l'hépatite b (vhb) d'hépatocytes humains
EP4130035A1 (fr) Anticorps et protéine de fusion pour traiter des coronavirus et leur utilisation
CN113637083A (zh) 用于治疗冠状病毒的融合蛋白及其应用
US20210009672A1 (en) Methods of treating or preventing liver fibrosis with inhibition of activins a & b
CN121175078A (zh) 治疗表达PDGFRα的癌症的方法
JP2026513850A (ja) Ｐｄｇｆｒアルファを発現するがんを治療する方法
CN121194990A (zh) 用于对表达PDGFRα的癌症进行成像的试剂和方法
WO2026067448A1 (fr) Anticorps anti-c-kit et son utilisation
HK40080094A (en) Antibody and fusion protein for treating coronaviruses and use thereof

Legal Events

Date Code Title Description
121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 23815182

Country of ref document: EP

Kind code of ref document: A1

NENP Non-entry into the national phase

Ref country code: DE

122 Ep: pct application non-entry in european phase

Ref document number: 23815182

Country of ref document: EP

Kind code of ref document: A1

122 Ep: pct application non-entry in european phase

Ref document number: 23815182

Country of ref document: EP

Kind code of ref document: A1